- Home
- NDRA vs ZVSA Comparison
NDRA vs ZVSA Comparison
Compare NDRA & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDRA
- ZVSA
- Stock Information
- Founded
- NDRA 2007
- ZVSA 2014
- Country
- NDRA United States
- ZVSA United States
- Employees
- NDRA N/A
- ZVSA N/A
- Industry
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- NDRA Health Care
- ZVSA Health Care
- Exchange
- NDRA Nasdaq
- ZVSA Nasdaq
- Market Cap
- NDRA 3.0M
- ZVSA 3.5M
- IPO Year
- NDRA 2017
- ZVSA N/A
- Fundamental
- Price
- NDRA $4.33
- ZVSA $1.22
- Analyst Decision
- NDRA Strong Buy
- ZVSA Strong Buy
- Analyst Count
- NDRA 1
- ZVSA 1
- Target Price
- NDRA $14,000.00
- ZVSA $240.00
- AVG Volume (30 Days)
- NDRA 13.9K
- ZVSA 69.7K
- Earning Date
- NDRA 03-27-2025
- ZVSA 03-24-2025
- Dividend Yield
- NDRA N/A
- ZVSA N/A
- EPS Growth
- NDRA N/A
- ZVSA N/A
- EPS
- NDRA N/A
- ZVSA N/A
- Revenue
- NDRA N/A
- ZVSA N/A
- Revenue This Year
- NDRA N/A
- ZVSA N/A
- Revenue Next Year
- NDRA N/A
- ZVSA N/A
- P/E Ratio
- NDRA N/A
- ZVSA N/A
- Revenue Growth
- NDRA N/A
- ZVSA N/A
- 52 Week Low
- NDRA $4.01
- ZVSA $0.98
- 52 Week High
- NDRA $2,170.00
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- NDRA 35.49
- ZVSA 44.26
- Support Level
- NDRA $4.62
- ZVSA $1.12
- Resistance Level
- NDRA $5.40
- ZVSA $1.29
- Average True Range (ATR)
- NDRA 0.30
- ZVSA 0.09
- MACD
- NDRA -0.05
- ZVSA -0.01
- Stochastic Oscillator
- NDRA 0.00
- ZVSA 37.04
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.